[go: up one dir, main page]

MA33197B1 - Inhibiteurs de tripeptide époxy cétone protéases cristallines - Google Patents

Inhibiteurs de tripeptide époxy cétone protéases cristallines

Info

Publication number
MA33197B1
MA33197B1 MA34254A MA34254A MA33197B1 MA 33197 B1 MA33197 B1 MA 33197B1 MA 34254 A MA34254 A MA 34254A MA 34254 A MA34254 A MA 34254A MA 33197 B1 MA33197 B1 MA 33197B1
Authority
MA
Morocco
Prior art keywords
epoxy ketone
tripeptide inhibitors
protease
crystalline
crystalline protease
Prior art date
Application number
MA34254A
Other languages
Arabic (ar)
English (en)
Inventor
Pasit Phiasivongsa
Louis C Sehl
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42738216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33197(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of MA33197B1 publication Critical patent/MA33197B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)

Abstract

L'invention porte sur des composés tripeptide céto époxyde cristallins, sur leurs procédés de préparation et sur des compositions pharmaceutiques apparentées.
MA34254A 2009-03-20 2010-03-22 Inhibiteurs de tripeptide époxy cétone protéases cristallines MA33197B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16219609P 2009-03-20 2009-03-20
US18056109P 2009-05-22 2009-05-22
PCT/US2010/028126 WO2010108172A1 (fr) 2009-03-20 2010-03-22 Inhibiteurs de tripeptide époxy cétone protéases cristallines

Publications (1)

Publication Number Publication Date
MA33197B1 true MA33197B1 (fr) 2012-04-02

Family

ID=42738216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34254A MA33197B1 (fr) 2009-03-20 2010-03-22 Inhibiteurs de tripeptide époxy cétone protéases cristallines

Country Status (45)

Country Link
US (5) US8604215B2 (fr)
EP (2) EP2813241B1 (fr)
JP (1) JP5723357B2 (fr)
KR (1) KR101729344B1 (fr)
CN (1) CN102428075B (fr)
AP (1) AP3513A (fr)
AR (1) AR075899A1 (fr)
AU (1) AU2010226410B2 (fr)
BR (1) BRPI1009369A2 (fr)
CA (1) CA2755971C (fr)
CL (1) CL2011002326A1 (fr)
CO (1) CO6430433A2 (fr)
CR (1) CR20110491A (fr)
CU (1) CU20110176A7 (fr)
CY (1) CY1118359T1 (fr)
DK (2) DK2813241T3 (fr)
DO (1) DOP2011000286A (fr)
EA (2) EA024672B1 (fr)
EC (1) ECSP11011341A (fr)
ES (2) ES2527619T3 (fr)
GE (1) GEP20156392B (fr)
HK (2) HK1162476A1 (fr)
HN (1) HN2011002459A (fr)
HR (2) HRP20150014T1 (fr)
HU (1) HUE032430T2 (fr)
IL (1) IL215174A (fr)
LT (1) LT2813241T (fr)
MA (1) MA33197B1 (fr)
ME (1) ME01277B (fr)
MX (2) MX343562B (fr)
MY (1) MY156522A (fr)
NI (1) NI201100170A (fr)
NZ (2) NZ618432A (fr)
PE (1) PE20120645A1 (fr)
PL (2) PL2408758T3 (fr)
PT (2) PT2813241T (fr)
RS (2) RS53746B1 (fr)
SA (2) SA114350283B1 (fr)
SG (2) SG2014011373A (fr)
SI (2) SI2813241T1 (fr)
SM (3) SMT201700068T1 (fr)
TN (1) TN2011000470A1 (fr)
TW (1) TWI504598B (fr)
WO (1) WO2010108172A1 (fr)
ZA (2) ZA201106826B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2623113T1 (sl) 2005-11-09 2017-08-31 Onyx Therapeutics, Inc. Spojina za inhibicijo encimov
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
PL2207791T5 (pl) 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
KR20110073584A (ko) 2008-10-21 2011-06-29 오닉스 세라퓨틱스, 인크. 펩티드 에폭시케톤과의 병용 요법
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
PT3178321T (pt) 2009-10-07 2019-08-01 Dow Agrosciences Llc Misturas fungicidas sinérgicas de epoxiconazol para o controlo de fungos em cereais
EP2498793B1 (fr) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib pour l'utilsation dans la suppression des metastases
EP2542238B1 (fr) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Composés pour inhibition de l'immunoprotéasome
WO2011136905A2 (fr) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Inhibiteur d'immunoprotéasome de peptide époxycétone cristallin
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN104540959B (zh) * 2012-08-10 2018-11-13 味之素株式会社 γ-谷氨酰缬氨酰甘氨酸晶体的制备方法
UY35091A (es) * 2012-10-24 2014-05-30 Onyx Therapeutics Inc Formulaciones de liberacion modificada para oprozomib
CN104883884B (zh) 2012-12-28 2018-03-23 美国陶氏益农公司 用于谷物里的真菌防治的协同增效杀真菌混合物
WO2015100184A1 (fr) 2013-12-26 2015-07-02 Dow Agrosciences Llc Utilisation de picolinamides macrocycliques en tant que fongicides
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
CN104974221B (zh) * 2014-04-03 2020-10-23 中国医学科学院药物研究所 二肽及三肽类蛋白酶体抑制剂及其制法和药物用途
US9955691B2 (en) 2014-07-08 2018-05-01 Dow Agrosciences Llc Macrocyclic picolinamides as fungicides
WO2016069479A1 (fr) 2014-10-27 2016-05-06 Apicore Us Llc Procédés de préparation de carfilzomib et d'intermédiaires de celui-ci
AU2015374459A1 (en) 2014-12-30 2017-06-29 Dow Agrosciences Llc Picolinamide compounds with fungicidal activity
RU2703402C2 (ru) * 2014-12-30 2019-10-16 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пиколинамиды с фунгицидной активностью
RU2702697C2 (ru) 2014-12-30 2019-10-09 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Использование пиколинамидных соединений с фунгицидной активностью
WO2016109304A1 (fr) 2014-12-30 2016-07-07 Dow Agrosciences Llc Picolinamides utilisés en tant que fongicides
ES2815673T3 (es) 2014-12-30 2021-03-30 Dow Agrosciences Llc Compuestos de picolinamida con actividad fungicida
CN105949279A (zh) * 2016-04-27 2016-09-21 浙江大学 蛋白酶体抑制剂Oprozomib及其类似物的制备方法
KR102571568B1 (ko) 2016-06-29 2023-08-25 케자르 라이프 사이언스 펩티드 에폭시케톤 면역프로테아제 저해제 및 그 전구체의 제조 방법
CA3029032A1 (fr) 2016-06-29 2018-01-04 Henry Johnson Sels cristallins d'un inhibiteur peptide d'immunoproteasome epoxycetone
WO2018044991A1 (fr) 2016-08-30 2018-03-08 Dow Agrosciences Llc Composés de thiopicolinamide à activité fongicide
US10244754B2 (en) 2016-08-30 2019-04-02 Dow Agrosciences Llc Picolinamide N-oxide compounds with fungicidal activity
WO2018045010A1 (fr) 2016-08-30 2018-03-08 Dow Agrosciences Llc Composés de pyrido -1,3-oxazine -2,4-dione à activité fongicide
US10214490B2 (en) 2016-08-30 2019-02-26 Dow Agrosciences Llc Picolinamides as fungicides
US20180078532A1 (en) 2016-09-21 2018-03-22 Amgen Inc. Immediate release formulations for oprozomib
US20180161279A1 (en) 2016-12-14 2018-06-14 Amgen Inc. Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
BR102018000183B1 (pt) 2017-01-05 2023-04-25 Dow Agrosciences Llc Picolinamidas, composição para controle de um patógeno fúngico, e método para controle e prevenção de um ataque por fungos em uma planta
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
CA3062074A1 (fr) 2017-05-02 2018-11-08 Dow Agrosciences Llc Utilisation d'un compose picolinamide acyclique en tant que fongicide pour lutter contre des maladies fongiques sur des gazons
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
CA3075714A1 (fr) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Polytherapie pour le traitement du cancer
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
WO2020081382A1 (fr) 2018-10-15 2020-04-23 Dow Agrosciences Llc Procédés de synthèse d'oxypicolinamides
CN118255835A (zh) * 2022-12-27 2024-06-28 上海美悦生物科技发展有限公司 三肽环氧酮化合物、药物组合物及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5071957A (en) 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0732399A3 (fr) 1990-03-05 1997-03-12 Cephalon Inc Protéases analogues à la chymotrypsine et leurs inhibiteurs
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
ATE195553T1 (de) * 1992-06-09 2000-09-15 Chiron Corp Kristallisierung von m-csf
GB9300048D0 (en) 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
TW380137B (en) 1994-03-04 2000-01-21 Merck & Co Inc Process for making an epoxide
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
DE19505263A1 (de) 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
WO1998010779A1 (fr) 1996-09-13 1998-03-19 New York University Methode pour traiter des maladies parasitaires avec des inhibiteurs de proteasome
EP1136498A1 (fr) 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérines protéases, notamment de NS3 protéase du virus de l'hépatite c
ATE212037T1 (de) 1996-10-18 2002-02-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
WO1998056422A1 (fr) 1997-06-13 1998-12-17 The University Of Kansas Compositions de medicaments ou de promedicaments polaires a duree de conservation prolongee et procede de fabrication de ces compositions
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6099851A (en) 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
IL142647A0 (en) 1998-10-20 2002-03-10 Millenium Pharmaceuticals Inc A method and kit for measuring proteasome activity
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
WO2001028579A2 (fr) 1999-10-20 2001-04-26 Osteoscreen, Inc. Inhibiteurs de l'activite de proteasome pour favoriser la croissance osseuse et la pousse des cheveux
AU2002218133A1 (en) 2000-10-12 2002-04-22 Viromics Gmbh Agents for the treatment of viral infections
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
EP1355910B1 (fr) 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation de composes d'acide boronique
EP1392355B1 (fr) 2001-05-21 2007-02-14 Alcon, Inc. Utilisation d'inhibiteurs de proteasome pour traiter des secheresses de l'oeil
EP1463719A2 (fr) 2002-01-08 2004-10-06 Eisai Co., Ltd Analogues d'eponemycine et d'epoxomicine et leurs utilisations
US20040116329A1 (en) 2002-01-29 2004-06-17 Epstein Stephen E. Inhibition of proteasomes to prevent restenosis
AU2003220685A1 (en) 2002-04-09 2003-10-27 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2003249682A1 (en) 2002-06-03 2003-12-19 Als Therapy Development Foundation Treatment of neurodegenerative diseases using proteasome modulators
US20030224469A1 (en) 2002-06-03 2003-12-04 Buchholz Tonia J. Methods and kits for assays utilizing fluorescence polarization
US20040167139A1 (en) 2002-07-26 2004-08-26 Potter David A. Methods of treating cancer
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
ATE414508T1 (de) 2003-04-08 2008-12-15 Novartis Pharma Gmbh Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
ATE506456T1 (de) 2003-06-10 2011-05-15 David Gladstone Inst Verfahren zur behandlung von lentivirusinfektionen
US7012063B2 (en) 2003-06-13 2006-03-14 Children's Medical Center Corporation Reducing axon degeneration with proteasome inhibitors
EP3238708A1 (fr) 2003-12-31 2017-11-01 CyDex Pharmaceuticals, Inc. Formulation pour inhalation à base de cyclodextrine et de corticostéroïde
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US20050228031A1 (en) * 2004-04-13 2005-10-13 Bilodeau Mark T Tyrosine kinase inhibitors
EP1745064B1 (fr) 2004-04-15 2011-01-05 Proteolix, Inc. Composés pour l'inhibition d'une enzyme de protéasome
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US20050256324A1 (en) 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
SI2030981T1 (sl) 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima
CN101044157B (zh) * 2004-08-06 2011-07-13 普罗特奥里克斯公司 用于抑制蛋白酶体的化合物
WO2006045066A2 (fr) 2004-10-20 2006-04-27 Proteolix, Inc. Composes pour inhibition d'enzymes
PT2261236E (pt) 2004-12-07 2015-10-30 Onyx Therapeutics Inc Composição para a inibição de proteassoma
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2006099261A2 (fr) 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Inhibiteurs puissants et spécifiques d'immunoprotéasomes
EP1876893B1 (fr) 2005-04-15 2012-04-11 Geron Corporation Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
SI2623113T1 (sl) 2005-11-09 2017-08-31 Onyx Therapeutics, Inc. Spojina za inhibicijo encimov
AR057227A1 (es) 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007122686A1 (fr) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. Composes benzimidazole
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
WO2008033807A2 (fr) 2006-09-13 2008-03-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combinaisons synergiques d'oxydants mitochondriaux antinéoplasiques se liant au thiol et d'inhibiteurs du protéasome antinéoplasiques pour le traitement du cancer
US8601054B2 (en) * 2006-12-07 2013-12-03 International Business Machines Corporation Project-related communications
CA2676387A1 (fr) 2007-01-23 2008-07-31 Gloucester Pharmaceuticals, Inc. Polytherapie
WO2008140782A2 (fr) * 2007-05-10 2008-11-20 Proteolix, Inc. Composés d'inhibition enzymatique
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20140042932A (ko) 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
PL2207791T5 (pl) 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
EP2212334B1 (fr) 2007-10-16 2012-08-15 Millennium Pharmaceuticals, Inc. Inhibiteurs de protéasomes
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CN103497232A (zh) 2008-06-17 2014-01-08 米伦纽姆医药公司 硼酸酯化合物及其医药组合物
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
KR20110073584A (ko) 2008-10-21 2011-06-29 오닉스 세라퓨틱스, 인크. 펩티드 에폭시케톤과의 병용 요법
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
CN101928329B (zh) 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
EP2498793B1 (fr) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib pour l'utilsation dans la suppression des metastases
EP2542238B1 (fr) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Composés pour inhibition de l'immunoprotéasome
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
WO2011136905A2 (fr) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Inhibiteur d'immunoprotéasome de peptide époxycétone cristallin

Also Published As

Publication number Publication date
PL2813241T3 (pl) 2017-04-28
SMT201500009B (it) 2015-03-05
PE20120645A1 (es) 2012-06-07
BRPI1009369A2 (pt) 2016-10-11
HK1162476A1 (en) 2012-08-31
TW201043623A (en) 2010-12-16
US20120077855A1 (en) 2012-03-29
US8604215B2 (en) 2013-12-10
ES2527619T3 (es) 2015-01-27
CN102428075B (zh) 2016-05-11
PT2813241T (pt) 2016-12-23
CN102428075A (zh) 2012-04-25
ES2614557T3 (es) 2017-05-31
PL2408758T3 (pl) 2015-03-31
GEP20156392B (en) 2015-11-10
WO2010108172A1 (fr) 2010-09-23
ZA201106826B (en) 2018-11-28
EA201300860A1 (ru) 2014-04-30
CY1118359T1 (el) 2017-06-28
EP2408758A1 (fr) 2012-01-25
HN2011002459A (es) 2015-03-16
ZA201601686B (en) 2016-11-30
TN2011000470A1 (en) 2013-03-27
AU2010226410B2 (en) 2015-09-17
MY156522A (en) 2016-02-26
DOP2011000286A (es) 2011-10-15
US20140024804A1 (en) 2014-01-23
EP2408758B1 (fr) 2014-10-22
SMT201700068T1 (it) 2017-03-08
LT2813241T (lt) 2017-01-10
US9051353B2 (en) 2015-06-09
EA201171151A1 (ru) 2012-04-30
NZ618432A (en) 2015-04-24
SI2408758T1 (sl) 2015-01-30
SG174446A1 (en) 2011-10-28
EA024672B1 (ru) 2016-10-31
SMT201700068B (it) 2017-03-08
CA2755971C (fr) 2017-05-16
DK2408758T3 (da) 2014-12-01
KR20110132577A (ko) 2011-12-08
NI201100170A (es) 2012-02-21
ME01277B (me) 2010-03-22
SA110310221B1 (ar) 2014-04-28
MX2011009777A (es) 2011-10-17
JP5723357B2 (ja) 2015-05-27
JP2012521363A (ja) 2012-09-13
AP2013007137A0 (en) 2013-09-30
RS53746B1 (en) 2015-06-30
AR075899A1 (es) 2011-05-04
EP2408758A4 (fr) 2012-09-05
AU2010226410A1 (en) 2011-11-03
US20150175656A1 (en) 2015-06-25
NZ595847A (en) 2013-12-20
HRP20161654T1 (hr) 2017-01-27
HRP20150014T1 (hr) 2015-02-27
US20100240903A1 (en) 2010-09-23
CA2755971A1 (fr) 2010-09-23
EA020973B1 (ru) 2015-03-31
DK2813241T3 (en) 2017-01-16
IL215174A (en) 2016-03-31
AP3513A (en) 2016-01-05
HK1204952A1 (en) 2015-12-11
CR20110491A (es) 2012-01-19
EP2813241A1 (fr) 2014-12-17
SA114350283B1 (ar) 2016-06-08
CU20110176A7 (es) 2012-04-15
IL215174A0 (en) 2011-12-29
MX343562B (es) 2016-11-09
SG2014011373A (en) 2014-05-29
ECSP11011341A (es) 2011-10-31
RS55431B1 (sr) 2017-04-28
TWI504598B (zh) 2015-10-21
EP2813241B1 (fr) 2016-11-16
SI2813241T1 (sl) 2017-03-31
HUE032430T2 (en) 2017-09-28
US9403868B2 (en) 2016-08-02
KR101729344B1 (ko) 2017-04-21
CO6430433A2 (es) 2012-04-30
PT2408758E (pt) 2014-11-04
CL2011002326A1 (es) 2012-03-23
US20120088903A1 (en) 2012-04-12
US8822512B2 (en) 2014-09-02

Similar Documents

Publication Publication Date Title
MA33197B1 (fr) Inhibiteurs de tripeptide époxy cétone protéases cristallines
UA97502C2 (ru) Кристаллическая твердая основа разагилина
TN2009000446A1 (en) P70 s6 kinase inhibitors
WO2011032169A3 (fr) Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MX341197B (es) Compuestos de isoindol 5 - sustituidos.
GEP20135964B (en) Inhibitors of beta-secretase
MX2009000884A (es) Derivados de piridizinona.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
MY162157A (en) Substituted indole mcl-1 inhibitors
EP2367839A4 (fr) Procédés et compositions permettant d'empêcher la germination et l'excroissance des spores de c. difficile
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MX2010000593A (es) Aumentador del vigor de una planta.
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MX2012004780A (es) Inhibidores de akt.
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
WO2011009039A3 (fr) Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
GEP20135806B (en) Lactams as beta secretase inhibitors
WO2012075015A3 (fr) Compositions pharmaceutiques orales de métronidazole
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
TW200638932A (en) CCI-779 polymorph and use thereof